Skip to main content
SpringerLink
Log in

Intravesical chemotherapy in urinary bladder cancer

  • Intravesical Chemotherapy, Adriamycin, Bladder Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Monthly instillation therapy with Adriamycin in a standardized dose of 300 ng/ml/h together with a phosphate buffer at pH 7.4 seems to give satisfactory results in patients with primary bladder carcinoma in situ and in patients with secondary carcinoma in situ of the bladder who have previously received full courses of irradiation.

The side-effects are transient and few.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

  1. WHO Collaborating Centre for Research and Treatment of Urinary Bladder and Prostate Cancer, Radiumhemmet, Stockholm, Sweder

    Folke Edsmyr, Lennart Anderson & Pier-Luigi Esposti

Authors
  1. Folke Edsmyr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lennart Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pier-Luigi Esposti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edsmyr, F., Anderson, L. & Esposti, PL. Intravesical chemotherapy in urinary bladder cancer. Cancer Chemother. Pharmacol. 11 (Suppl 1), S67–S68 (1983). https://doi.org/10.1007/BF00256722

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00256722

Keywords

Search

Navigation